For the treatment of hypertension, the combination of an angiotensinconverting enzyme (ACE) inhibitor and a thiazide diuretic is supported by multiple lines of evidence, because these drugs have synergistic action and are expected to cancel out each other's adverse side effects. However, the longterm outcome of this combination antihypertensive therapy is not entirely clear. In the present multicenter open trial, we investigated the long-term efficacy and safety of combined antihypertensive therapy with an ACE inhibitor, lisinopril, and a thiazide diuretic, trichlormethiazide. A total of 466 patients with essential hypertension were treated with lisinopril alone (monotherapy group, n=360) or with a combination of lisinopril with trichlormethiazide (combination therapy group, n=106) for 1 year. The average blood pressure was effectively lowered to below 150/90mmHg in both the monotherapy and the combination therapy groups throughout the study period. The average maintenance dose of lisinopril was lower when combined with thiazide than when given alone (9.8 vs. 11.5mg/day, p<0.001). Dry cough was the major side effect of lisinopril; no severe adverse effects were observed. The incidence of cough was not significantly different between the monotherapy group (13.1%) and the combination therapy group (11.3%). The increase in serum potassium observed in the monotherapy group was reversed by the concurrent use of the thiazide From the 1Department
SUMMARY
For the treatment of hypertension, the combination of an angiotensinconverting enzyme (ACE) inhibitor and a thiazide diuretic is supported by multiple lines of evidence, because these drugs have synergistic action and are expected to cancel out each other's adverse side effects. However, the longterm outcome of this combination antihypertensive therapy is not entirely clear. In the present multicenter open trial, we investigated the long-term efficacy and safety of combined antihypertensive therapy with an ACE inhibitor, lisinopril, and a thiazide diuretic, trichlormethiazide. A total of 466 patients with essential hypertension were treated with lisinopril alone (monotherapy group, n=360) or with a combination of lisinopril with trichlormethiazide (combination therapy group, n=106) for 1 year. The average blood pressure was effectively lowered to below 150/90mmHg in both the monotherapy and the combination therapy groups throughout the study period. The average maintenance dose of lisinopril was lower when combined with thiazide than when given alone (9.8 vs. 11.5mg/day, p<0.001). Dry cough was the major side effect of lisinopril; no severe adverse effects were observed. The incidence of cough was not significantly different between the monotherapy group (13.1%) and the combination therapy group (11.3%). The increase in serum potassium observed in the monotherapy group was reversed by the concurrent use of the thiazide 
RESULTS
A total of 514 patients were initially registered in the study, however , 48
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were not included because of failure to meet the inclusion criteria or violation of the study protocol. Thus, 466 patients, 360 in the M group and 106 in the C group, met the inclusion criteria and were enrolled. Of these patients, 11 (M9, C2) were transferred to other hospitals mainly because of changing the place of residence. Nine patients (M8, C1) decided not to visit the hospital due to personal reasons; however, follow-up inquiry by telephone revealed that they were doing well. The administration of lisinopril was stopped in 7 patients (M5, C2) because the hypotensive effect was excessive. Conversely, in 9 patients (M6, C3), addi- tional antihypertensive medication was needed to control blood pressure. Lisinopril was discontinued in 61 patients because of side effects; in most cases, dry cough was the cause for discontinuation (M47, C12). The incidence of cough was insignificantly lower in the C group than in the M group (11.3% vs. 13.1%). Two patients in the C group developed allergic dermatitis and lisinopril was stopped. The study protocol was abandoned in 1 patient in the C group because of pneumonia and in 2 patients in the M group because of aggravation of concomitant diseases (gastric ulcer and ventricular arrhythmia). Twelve (M9, C3) patients were excluded from the data analysis because of poor compliance. Body weight did not change significantly during the study period. Table III presents the blood chemistry data before and after lisinopril treatment. There were no significant changes in liver or renal function, or serum protein and lipids. With regard to the electrolytes, the serum potassium was significantly increased by lisinopril treatment in the M group but not in the C group. Fasting blood glucose was significantly reduced after lisinopril treatment in the M group; the reduction observed in the C group was not significant.
DISCUSSION
In the present study, long-term treatment with lisinopril, either alone or in combination with a thiazide diuretic, was effective in controlling the blood pressure of patients with essential hypertension. Moreover, the data suggest that the concurrent use of a thiazide diuretic can reduce the maintenance dose of lisinopril. The major adverse effect of the lisinopril therapy was dry cough, as is the case with ACE inhibitors.13) Although this is not a severe side effect, a total of 12.6% patients stopped taking lisinopril because of this side effect. The incidence of cough induced by lisinopril in this study is comparable to that seen with other ACE inhibitors.13) Although the mechanism of cough induced by ACE inhibitors is not fully understood, it has been speculated that a buildup of ACE substrates other than angiotensin I, such as bradykinin and substance P, may be involved.1 Thiazide diuretics have been shown to potentiate acetylcholine-induced airway constriction.15) It has also been reported that thiazides, when aerosolized and inhaled, inhibited a capsaicin-induced increase in airway resistance and cough.1 Therefore, it is possible that the addition of thiazides affects the incidence of cough in patients treated with ACE inhibitors. In the present study, the incidence of cough induced by lisinopril did not differ between the monotherapy group and the combination therapy group. McEwan et al. reported that the concurrent use of cyclooxygenase inhibitors attenuates the ACE inhibitor-induced cough.1 However, the long-term use of nonsteroidal antiinflammatory drugs is questionable because it may cause other adverse effects. Thus, the occurrence of cough seems an intractable drawback of ACE inhibitors, although it is not a severe side effect.
Hyperkalemia is another possible side effect of ACE inhibitors. Angiotensin II, a stimulator of aldosterone production, is reduced by ACE inhibitors. Because aldosterone promotes potassium excretion in exchange for sodium reabsorption In summary, the results of the present study show that long-term antihypertensive treatment with an ACE inhibitor, lisinopril, was effective in controlling blood pressure both when given as monotherapy and when combined with a thiazide diuretic. Dry cough was the major side effect of lisinopril; no severe adverse effects were observed. The concurrent use of a thiazide diuretic reduced the maintenance dose of lisinopril and canceled the increase in serum potassium. However, the incidence of cough was not significantly different between the monotherapy and the combination therapy groups. The effects of lisinopril on glucose and lipid metabolism were small, if any, in the long-term treatment of hypertension. Thus, the present data delineate the effectiveness and safety of combination antihypertensive therapy with lisinopril and a thiazide in comparison with monotherapy with lisinopril.
